Scottish diagnostics specialist FlexMedical Solutions has marked its 10-year anniversary by entering a strategic collaboration with France-headquartered Linxens aimed at developing and commercialising electrode components for diagnostic devices used in the healthcare industry.
FlexMedical’s CEO and Co-founder Kevin Fallon said: “The partnership with Linxens opens up the point-of-care testing market in North America and Asia, as we continue to internationalise the business we founded a decade ago.”
Livingston-based FlexMedical is a contract design, development, and manufacturing organisation working with a range of clients from early stage university spinouts to multinational original equipment manufacturers (OEMs), specialising in diagnostics and biosensors, including wearable technologies.
Linxens is a global leader in the electronics industry, with 7 R&D centres and 8 factories, employing over 3,000 people worldwide.
Minh Le, Vice-President of Linxens Healthcare, said: “This collaboration expands our biosensor portfolio by integrating functionalisation capabilities, enabling us to deliver end-to-end solutions – from flex-PCB or printed electrodes to fully functional sensor platforms. Together, we streamline the journey from R&D to mass production, accelerating the delivery of innovative diagnostic solutions.”
Kevin Fallon added: “The diagnostics industry has changed post COVID, wearable technology has risen up the agenda, along with AI having an increasing impact, and we think the t collaboration with Linxens will keep us ahead of the curve while significantly improving our market reach ”
Fellow directors Murray Whyte and Donogh FitzGerald are taking up new roles in the company’s leadership team, with Whyte moving from CTO to the newly created position of Chief Growth Officer, with FitzGerald switching to CTO from Chief Science Officer. FlexMedical is also planning to hire a Technical Director and product developers across science and engineering.
The business continues to be self-funded although Fallon has not ruled out external investment at some point: “We are quite regularly approached by private equity firms and others with a strategic interest.”
FlexMedical is forecasting a double-digit increase on 2024 revenues in the current financial year.
